Which visual acuity measurements define high-quality care for patients with neovascular age-related macular degeneration treated with ranibizumab?
Which visual acuity measurements define high-quality care for patients with neovascular age-related macular degeneration treated with ranibizumab?
Purpose: the purpose of this study is to define which visual acuity (VA) measurements are the best indicators of high-quality care for patients receiving intravitreal ranibizumab for neovascular age-related macular degeneration (nAMD).
Methods: analysis of prospectively collected data recorded within an electronic medical record system on treatment-naive, first-eligible eyes with nAMD, treated with ranibizumab using an as-needed treatment regimen with a minimum follow-up of 1 year. Data collection included the following: age, gender, laterality, type of nAMD, VA, central 1 mm OCT retinal thickness, number of intravitreal injections, and number of follow-up assessments.
Results: data were available on the first-treated eye from 406 patients with at least 1 year follow-up; of these, 198 had data at 2 years. The mean baseline VA of 54.4 Early Treatment Diabetic Retinopathy Study letters improved to 58.5 letters at 12 months and to 56.8 letters at 24 months. The mean VA changes from baseline to 1 year were +6.5, +7.5, +1.7, and −1.5 letters, respectively, for baseline VA categories of 23–35, 36–55, 56–70, and >70 letters. Change in mean VA from the end of the loading phase to year 1 ranged from −2.9 to +1.4 letters for the different baseline VA categories. The mean number of injections were similar across baseline VA categories ranging from 5.7 to 6.0 injections in year 1 and from 3.3 to 3.8 in year 2.
Conclusions: this large, real-world series demonstrates that mean change in VA is largely a function of selection criteria and baseline VA. The quality of a service is therefore better judged by actual VA outcomes and maintenance of vision after the loading phase.
agerelated macular degeneration, neovascular, ranibizumab, visual acuity
56-64
Ross, A.H.
0f83a970-ca2c-400a-83f8-b47bcbf221f9
Donachie, P.H.J.
ff9da07a-e148-4e14-97bf-5333b834b3f0
Sallam, A.
150f19eb-a53c-4df1-b426-afe4e73a6d46
Stratton, I.M.
772f25b9-23c0-4240-a3f6-1e76b03b172f
Mohamed, Q.
93a6e7f4-875a-4009-a326-d907d1402998
Scanlon, P.H.
4e3d2310-c79e-42db-ae29-7a7d6b278aa3
Kirkpatrick, J.N.
2d68acaa-ea44-4aba-a125-1750317dbaab
Johnston, R.L.
51222551-d565-4e41-a042-214ac3c242ad
January 2013
Ross, A.H.
0f83a970-ca2c-400a-83f8-b47bcbf221f9
Donachie, P.H.J.
ff9da07a-e148-4e14-97bf-5333b834b3f0
Sallam, A.
150f19eb-a53c-4df1-b426-afe4e73a6d46
Stratton, I.M.
772f25b9-23c0-4240-a3f6-1e76b03b172f
Mohamed, Q.
93a6e7f4-875a-4009-a326-d907d1402998
Scanlon, P.H.
4e3d2310-c79e-42db-ae29-7a7d6b278aa3
Kirkpatrick, J.N.
2d68acaa-ea44-4aba-a125-1750317dbaab
Johnston, R.L.
51222551-d565-4e41-a042-214ac3c242ad
Ross, A.H., Donachie, P.H.J., Sallam, A., Stratton, I.M., Mohamed, Q., Scanlon, P.H., Kirkpatrick, J.N. and Johnston, R.L.
(2013)
Which visual acuity measurements define high-quality care for patients with neovascular age-related macular degeneration treated with ranibizumab?
Eye (Basingstoke), 27 (1), .
(doi:10.1038/eye.2012.225).
Abstract
Purpose: the purpose of this study is to define which visual acuity (VA) measurements are the best indicators of high-quality care for patients receiving intravitreal ranibizumab for neovascular age-related macular degeneration (nAMD).
Methods: analysis of prospectively collected data recorded within an electronic medical record system on treatment-naive, first-eligible eyes with nAMD, treated with ranibizumab using an as-needed treatment regimen with a minimum follow-up of 1 year. Data collection included the following: age, gender, laterality, type of nAMD, VA, central 1 mm OCT retinal thickness, number of intravitreal injections, and number of follow-up assessments.
Results: data were available on the first-treated eye from 406 patients with at least 1 year follow-up; of these, 198 had data at 2 years. The mean baseline VA of 54.4 Early Treatment Diabetic Retinopathy Study letters improved to 58.5 letters at 12 months and to 56.8 letters at 24 months. The mean VA changes from baseline to 1 year were +6.5, +7.5, +1.7, and −1.5 letters, respectively, for baseline VA categories of 23–35, 36–55, 56–70, and >70 letters. Change in mean VA from the end of the loading phase to year 1 ranged from −2.9 to +1.4 letters for the different baseline VA categories. The mean number of injections were similar across baseline VA categories ranging from 5.7 to 6.0 injections in year 1 and from 3.3 to 3.8 in year 2.
Conclusions: this large, real-world series demonstrates that mean change in VA is largely a function of selection criteria and baseline VA. The quality of a service is therefore better judged by actual VA outcomes and maintenance of vision after the loading phase.
This record has no associated files available for download.
More information
Accepted/In Press date: 25 September 2012
e-pub ahead of print date: 23 November 2012
Published date: January 2013
Keywords:
agerelated macular degeneration, neovascular, ranibizumab, visual acuity
Identifiers
Local EPrints ID: 487146
URI: http://eprints.soton.ac.uk/id/eprint/487146
ISSN: 0950-222X
PURE UUID: 24b109c6-1aaf-4d85-9b06-f04624489c5a
Catalogue record
Date deposited: 14 Feb 2024 17:42
Last modified: 18 Mar 2024 04:01
Export record
Altmetrics
Contributors
Author:
A.H. Ross
Author:
P.H.J. Donachie
Author:
A. Sallam
Author:
I.M. Stratton
Author:
Q. Mohamed
Author:
P.H. Scanlon
Author:
J.N. Kirkpatrick
Author:
R.L. Johnston
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics